Intra-Cellular Therapies is a biopharmaceutical company that is developing novel drugs for the treatment of diseases and disorders of the Central Nervous System (CNS). The Company develops compounds that have the potential to treat a wide range of diseases associated with the central nervous system. Intra-Cellular Therapies is developing its lead drug candidate, lumateperone, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, depression, and other neuropsychiatric and neurological disorders.

TypePublic
HQNew York, US
Founded2002
Size (employees)41 (est)
Websiteintracellulartherapies.com
Intra-Cellular Therapies was founded in 2002 and is headquartered in New York, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Intra-Cellular Therapies Office Locations

Intra-Cellular Therapies has an office in New York
New York, US (HQ)
900 430 E 29th St
Show all (1)
Report incorrect company information

Intra-Cellular Therapies Financials and Metrics

Intra-Cellular Therapies Revenue

Intra-Cellular Therapies's revenue was reported to be $245.84 k in FY, 2017
USD

Net income (Q2, 2018)

(72.9 m)

EBIT (Q2, 2018)

(76.3 m)

Market capitalization (20-Sep-2018)

1.2 b

Closing stock price (20-Sep-2018)

21.8

Cash (30-Jun-2018)

69.8 m
Intra-Cellular Therapies's current market capitalization is $1.2 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

2.7 m577.3 k91.4 k330.7 k245.8 k

Revenue growth, %

(79%)(84%)262%

General and administrative expense

10.3 m18.2 m24.8 m23.7 m

R&D expense

21.2 m87.7 m93.8 m79.4 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Revenue

668 k167.8 k219.2 k124.4 k3.3 k57.4 k124.4 k3.3 k228.4 k4.4 k95.3 k114.7 k

General and administrative expense

1.3 m1.9 m2.1 m2.6 m3.8 m4 m3.9 m5.1 m6.5 m6.3 m6.3 m6.3 m6.4 m13.1 m

R&D expense

4.2 m2.8 m2.7 m4 m18.6 m17.8 m28.5 m23.4 m25.3 m23.9 m21.5 m12.5 m30.7 m63.1 m

Operating expense total

5.5 m4.7 m4.8 m6.6 m22.4 m21.7 m32.3 m28.5 m31.8 m30.2 m27.8 m18.7 m37.1 m76.3 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

35.2 m61.3 m47.2 m48.6 m37.8 m

Accounts Receivable

336.3 k51.6 k30.7 k94.3 k

Inventories

762.2 k1.3 m8 m4 m

Current Assets

38.2 m131 m483.3 m388.2 m469.2 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Cash

44.1 m143.6 m91.1 m68.9 m100.8 m71.4 m332.8 m37.2 m52 m200.4 m23.6 m29.6 m74.4 m69.8 m

Accounts Receivable

251.3 k167.8 k219.2 k124.4 k3.3 k9.1 k51.6 k98.2 k1.3 k68.2 k61.9 k

Current Assets

47.1 m146.4 m141.2 m137.5 m236.5 m212.6 m512.3 m462.9 m446.8 m541.8 m371.6 m348.8 m443.2 m409.7 m

PP&E

75.7 k65.1 k63.9 k57.4 k559.7 k722.1 k785.5 k731.4 k718.7 k677.7 k605.7 k628.9 k1.3 m1.3 m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(30.7 m)(104.8 m)(116.4 m)(97.8 m)

Depreciation and Amortization

25.5 k139.6 k196.9 k213.9 k

Inventories

Accounts Payable

(1.3 m)(419.9 k)2.1 m2.4 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

Net Income

(4.9 m)(4.5 m)(4.5 m)(6.4 m)(22.3 m)(21.5 m)(32.2 m)(27.8 m)(30.8 m)(30.3 m)(26.9 m)(35.5 m)(72.9 m)

Depreciation and Amortization

82.5 k178.3 k

Accounts Payable

415.8 k503.9 k4.6 m4.9 m705 k2 m3.9 m5.4 m7.2 m3.9 m(794.7 k)

Cash From Operating Activities

(27 m)(60.6 m)
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics

Intra-Cellular Therapies Operating Metrics

FY, 2017

Patents and Patent Applications

80
Show all operating metrics

Intra-Cellular Therapies Revenue Breakdown

Embed Graph

Intra-Cellular Therapies revenue breakdown by business segment: 33.6% from License and collaboration revenue and 66.4% from Grant Revenue

Report incorrect company information

Intra-Cellular Therapies Company Life and Culture

Report incorrect company information